ReviewCurrent opinion in virology2016
Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma.
Review in Current opinion in virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 85 citations in OpenAlex.
- Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial.Oxidative medicine and cellular longevity · 2022Trial
- Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.World journal of gastroenterology · 2018Trial
- Evaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study.Medicine · 2025Observational
- Geographic diversity of human liver cancers mirrors global social inequalities.Frontiers in oncology · 2025Review
- Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication.Alimentary pharmacology & therapeutics · 2024Article
- Suppression of Innate Immunity by the Hepatitis C Virus (HCV): Revisiting the Specificity of Host-Virus Interactive Pathways.International journal of molecular sciences · 2023Review
- Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment.Life (Basel, Switzerland) · 2023Review
- Hepatocellular Carcinoma Prevention in the Era of Hepatitis C Elimination.International journal of molecular sciences · 2023Review
- Early Phase of Specific Cellular Immune Status Associates with HCV Infection Outcomes in Marmosets.Viruses · 2023Article
- Deciphering the Relationship between SARS-CoV-2 and Cancer.International journal of molecular sciences · 2023Review
- The care cascade for hepatitis C virus and prognosis of chronic hepatitis C patients treated with antiviral agents in a tertiary hospital.BMC gastroenterology · 2023Article
- Microbial Natural Products with Antiviral Activities, Including Anti-SARS-CoV-2: A Review.Molecules (Basel, Switzerland) · 2022Review
- Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment.World journal of gastroenterology · 2022Review
- Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective.Journal of personalized medicine · 2022Review
- [Occurrence and recurrence of hepatitis C-related hepatocellular carcinoma after direct antiviral treatment].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Review
- The Pannexin 1/Purinergic Receptor P2X4 Pathway Controls the Secretion of MicroRNA-Containing Exosomes by HCV-Infected Hepatocytes.Hepatology (Baltimore, Md.) · 2021Article
- Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?World journal of gastroenterology · 2021Review
- Review
- Viral Infection Modulates Mitochondrial Function.International journal of molecular sciences · 2021Review
- The Dark Side of the Force: When the Immune System Is the Fuel of Tumor Onset.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Hepatitis C virus (HCV) infection is one of the major causes of advanced liver disease and hepatocellular carcinoma (HCC) worldwide. While the knowledge about the molecular virology of HCV infection has markedly advanced, the molecular mechanisms of disease progression leading to fibrosis, cirrhosis and HCC are still unclear. Accumulating experimental and clinical studies indicate that HCV may drive hepatocarcinogenesis directly via its proteins or transcripts, and/or indirectly through induction of chronic liver inflammation. Despite the possibility to eradicate HCV infection through direct-acting antiviral treatment, the risk of HCC persists although specific biomarkers to estimate this risk are still missing. Thus, a better understanding of HCV-induced HCC and more physiological liver disease models are required to prevent cancer development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.